Computational Biology Market Size & Trend Report, 2024-2033
The global computational biology market size was estimated at USD 6.10 billion in 2023 and is projected to hit around USD 21.04 billion by 2033, growing at a CAGR of 13.18% during the forecast period from 2024 to 2033.
Key Takeaways:
Computational Biology Market Growth
The growing advancements in genomics and bioinformatics, increasing demand for personalized medicine, drug discovery and development, and the need for efficient data analysis in the life sciences are driving the growth of the market for computational biology. In addition, the rising application of artificial intelligence & machine learning to computational biology is anticipated to boost the market.
The COVID-19 pandemic accelerated the adoption of computational biology solutions, specifically in vaccine discovery & development and virus genomics research. High-performance computing and machine learning techniques contributed to analyzing gigantic datasets, recognizing potential drugs, and understanding the genetic map of viruses. Thus, the computational biology field has played an important role in the COVID-19 pandemic response efforts and is expected to witness continued expansion in post-pandemic research in life sciences.
There is an increasing adoption of AI innovation in the healthcare sector which includes medicine, pharmacology, and biotechnology, where it is majorly transforming drug discovery & development. According to the news article, published in January 2023, the drug discovery & development cost for a drug averages nearly USD 1.3 billion, giving a significant opportunity for AI-based technology in drug discovery. Moreover, according to a research paper, released by Nature, in February 2022, the adoption of AI into drug discovery & drug development has increased the pipeline almost nearly to 40% yearly. Furthermore, as per an interview with one of the healthcare investors, various drug-developing organizations are utilizing AI technology in multiple ways which include machine learning algorithms to identify & validate the potential of various drugs by predicting their effectiveness and safety. AI technology is further used in optimizing the design of drugs according to its effectiveness. Thus, the adoption of AI and ML in drug development promising opportunity and is anticipated to fuel the process of drug discovery, thereby, accelerating the market growth of computational biology over the forecast period.
Furthermore, in May 2022, a Germany-based company CureVac, and a Belgium-based company myNEO collaborated to work on specific cancer antigens in order to identify & develop new mRNA immunotherapies for the vaccines for cancer. myNEO used their biological databases & bioinformatics integrated with ML to identify & validate specific target areas to create strong immune responses. Similarly, in April 2023, IBM and Moderma collaborated to use generative AI along with quantum computing to develop advanced mRNA technology, which would be used in discovery & development of vaccines. Thus, these collaborations between organizations for vaccine discoveries & development are anticipated to drive the growth of the computational biology market in the coming years.
Computational Biology Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 6.90 Billion |
| Market Size by 2033 | USD 21.04 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 13.18% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Service, application, end-use, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | DNAnexus, Inc.; Illumina, Inc.; Thermo Fisher Scientific, Inc.; Schrodinger, Inc.; Compugen, Aganitha AI Inc.; Genedata AG; QIAGEN; Simulations Plus, Inc.; Fios Genomics. |
Segments Insights:
Service Insights
Based on service, software platforms segment accounted for the largest market share of 42.15% in 2023 and is expected to expand at the fastest CAGR from 2024 to 2033. Software platforms in computational biology typically encompass a wide range of tools and technologies, including bioinformatics software, data analysis platforms, modeling, and simulation software, etc. These tools are essential for the management and analysis of large volumes of biological data, such as genomics, proteomics, and structural biology data. Furthermore, increasing demand for personalized medicines and growing drug discovery & development are some of the major factors boosting the segment growth. For instance, in May 2023, Genialis, a company specializing in computational precision medicine, announced the launch of Genialis Expressions version 3.0. The software is designed to expedite the process of discovering translational and clinical biomarkers, shedding light on complicated biological mechanisms for novel disease treatment approaches. Thus, the rising demand for computational technology in personalized medicine and drug development is anticipated to fuel the market growth of the segment from 2023 to 2030.
The infrastructure & hardware segment is expected to grow at a significant CAGR of 12.23% from 2024 to 2033. Computational biology often requires access to high-performance computing resources to perform complex simulations and data analysis tasks. The demand for more powerful hardware infrastructure services to support these computations is expected to increase as computational biology research becomes better. Moreover, in February 2021, Rescale, a startup headquartered in California, that focuses on advancing scientific and engineering simulation through its software platform and hardware infrastructure, has secured USD 50 million in funding. Thus, the growing investments in various organizations are anticipated to boost the segment growth over the period.
Application Insights
Based on application, clinical trials held the maximum market share of 27.54% in 2023. This can be attributed to the surging demand for drug discovery & development, target identification & validation, and personalized medicines. Moreover, with the increasing availability of patient data, including genomics and electronic health records, computational biology is used to analyze and interpret these patients’ data for undertaking informed clinical trial decisions. In September 2023, OSE Immunotherapeutics SA announced a peer-reviewed study in the Annals of Oncology regarding the Phase 3 clinical trial known as Atalante-1. This trial evaluated the T-cell epitope tumor vaccine Tedopi as a monotherapy in individuals with advanced HLA-A2 positive or metastatic NSCLC, specifically in the third-line treatment setting for NSCLC cases showing secondary resistance to immune checkpoint inhibitors (ICI). Thus, these factors are anticipated to propel the growth of the segment over the forecast period.
The computational genomics segment is expected to expand at the fastest CAGR of 15.99% from 2024 to 2033. Computational genomics is a field that focuses on the analysis and interpretation of genomic data using computational methods and tools. The rising incidence of cancer has propelled the growth of innovative treatments, consequently driving the demand for computational genomics in oncology research. According to World Cancer Research Fund International, approximately 18.1 million cases of cancer were reported globally in 2020, with 9.3 million occurring in males and 8.8 million in females. Furthermore, in January 2023, the personalized cancer vaccine developed by Evaxion Biotech received fast-track designation (FTD) from the FDA in combination with Keytruda for individuals diagnosed with metastatic melanoma (MM). Hence, the segment is expected to grow exponentially over the forecast period.
End-use Insights
The industrial segment accounted for the largest market share of 63.19% in 2023. The expanding awareness of artificial methods in computational biology, which enhance the advanced visualization and analysis of biological structures, is a key driver for the growth of the industrial segment. With an increasing demand to gain deeper insights into the metabolic interactions of therapeutic substances within the pharmaceutical & biotechnology sectors, companies are anticipated to increase the usage of advanced technologies like machine learning and artificial intelligence. Thereby, expected to accelerate the progress in drug research & development, helping in substantial innovations within the domain.
Academic & research is expected to grow at the fastest CAGR from 2024 to 2033. This can be attributed to the substantial need for computational software to enhance genome analysis within the rising research and development activities conducted in various research organizations. Furthermore, the increase in collaborative efforts and investments between public and private entities to launch new research institutes is expected to accelerate the expansion of this segment.
Regional Insights
North America held the largest share of 49.73% of the global market in 2023. The dominant market share is primarily due to the robust U.S. biotechnology and biopharmaceutical industry, increasing demand for computational biology in research & academic institutions for various drug discovery & development, and other factors. Moreover, the presence of major companies & organizations is anticipated to impel the adoption of advanced computational biology for various applications. In addition, significant investment in health technology is projected to drive the need to improve patient outcomes, hence, propelling the growth of the market. Thus, continuous advancements in computational biology coupled with affordable adoption of artificial intelligence, and growing investments solidify the U.S. as the world's most lucrative market.
The Asia Pacific market is anticipated to expand at a significant CAGR of 15.65% from 2024 to 2033. This trend is mainly due to rapid growth in the region’s biopharmaceutical sectors, including China and India, which leads to rising investments in healthcare IT & life science sectors. Furthermore, the rising emergence of startups focusing on bioinformatics is anticipated to accelerate the growth of the market in the region. For instance, in April 2022, an India-based AI startup Algorithmic Biologics, was planning to build a molecular computing algorithm to collect and analyze biological data which includes RNA, DNA, and various other proteins. In addition, rising government investments in better healthcare IT are propelling market growth. Hence, such government initiatives, growing R&D services, and emerging startups are anticipated to increase the adoption of computational biology in the Asia Pacific region.
Key Companies & Market Share Insights
Key market players are involved in extensive R&D for developing cost-efficient and technologically advanced products. Several strategies, such as new product launches and mergers & acquisitions are being undertaken by these players to expand their market presence which is expected to create significant growth opportunities over the forecast period. For instance, in February 2023, Accenture invested in Ocean Genomics, which is a U.S.-based technology & AI company that focuses on advanced computational platforms. This investment is expected to assist biotechnology companies in the discovery & development of personalized medicines. Such strategic initiatives by organizations are anticipated to propel the growth of the market over the forecast period. Some of the key players operating in the global computational biology market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Computational Biology market.
By Service
By Application
By End-use
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Service Segment
1.2.2. Application Segment
1.2.3. End-use Segment
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Growing Adoption Of Bioinformatics Technology
3.3.2. Advancements In Genomic Research
3.3.3. Increasing Demand For Personalized Medicines
3.4. Market Restraint Analysis
3.4.1. Lack of Skilled Professional
3.4.2. Data Privacy And Security Concerns
3.5. Business Environment Analysis
3.5.1. PESTEL Analysis
3.5.2. Porter’s Five Forces Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Service Business Analysis
4.1. Computational Biology Market: Service Movement Analysis
4.2. Databases
4.2.1. Databases Market, 2021 - 2033
4.3. Infrastructure & Hardware
4.3.1. Infrastructure & Hardware, 2021 - 2033
4.4. Software Platform
4.4.1. Software Platform Market, 2021 - 2033
Chapter 5. Application Business Analysis
5.1. Computational Biology Market: Application Movement Analysis
5.2. Drug Discovery & Disease Modelling
5.2.1. Drug Discovery & Disease Modelling Market, 2021 - 2033
5.2.2. Target Identification
5.2.2.1. Target Identification Market, 2021 - 2033
5.2.3. Target Validation
5.2.3.1. Target Validation Market, 2021 - 2033
5.2.4. Lead Discovery
5.2.4.1. Lead Discovery Market, 2021 - 2033
5.2.5. Lead Optimization
5.2.5.1. Lead Optimization Market, 2021 - 2033
5.3. Preclinical Drug Development
5.3.1. Preclinical Drug Development Market, 2021 - 2033
5.3.2. Pharmacokinetics
5.3.2.1. Pharmacokinetics Market, 2021 - 2033
5.3.3. Pharmacodynamics
5.3.3.1. Pharmacodynamics Market, 2021 - 2033
5.4. Clinical Trials
5.4.1. Clinical Trials Market, 2021 - 2033
5.4.2. Phase I
5.4.2.1. Phase I Market, 2021 - 2033
5.4.3. Phase II
5.4.3.1. Phase II Market, 2021 - 2033
5.4.4. Phase III
5.4.4.1. Phase III Market, 2021 - 2033
5.4.5. Phase IV
5.4.5.1. Phase IV Market, 2021 - 2033
5.5. Computational Genomics
5.5.1. Computational Genomics Market, 2021 - 2033
5.6. Computational Proteomics
5.6.1. Computational Proteomics Market, 2021 - 2033
5.7. Others
5.7.1. Others Market, 2021 - 2033
Chapter 6. End-use Business Analysis
6.1. Computational Biology Market: End-use Movement Analysis
6.2. Academic & Research
6.2.1. Academic & Research Market, 2021 - 2033
6.3. Industrial
6.3.1. Industrial Market, 2021 - 2033
Chapter 7. Regional Business Analysis
7.1. Regional Market Snapshot
7.2. North America
7.2.1. North America Computational Biology Market, 2021 - 2033
7.2.2. U.S.
7.2.2.1. U.S. Computational Biology Market, 2021 - 2033
7.2.2.2. Key Country Dynamics
7.2.2.3. Competitive Scenario
7.2.3. Canada
7.2.3.1. Canada Computational Biology Market, 2021 - 2033
7.2.3.2. Key Country Dynamics
7.2.3.3. Competitive Scenario
7.3. Europe
7.3.1. Europe Computational Biology Market, 2021 - 2033
7.3.2. UK
7.3.2.1. UK Computational Biology Market, 2021 - 2033
7.3.2.2. Key Country Dynamics
7.3.2.3. Competitive Scenario
7.3.3. Germany
7.3.3.1. Germany Computational Biology Market, 2021 - 2033
7.3.3.2. Key Country Dynamics
7.3.3.3. Competitive Scenario
7.3.4. Spain
7.3.4.1. Spain Computational Biology Market, 2021 - 2033
7.3.4.2. Key Country Dynamics
7.3.4.3. Competitive Scenario
7.3.5. France
7.3.5.1. France Computational Biology Market, 2021 - 2033
7.3.5.2. Key Country Dynamics
7.3.5.3. Competitive Scenario
7.3.6. Italy
7.3.6.1. Italy Computational Biology Market, 2021 - 2033
7.3.6.2. Key Country Dynamics
7.3.6.3. Competitive Scenario
7.3.7. Denmark
7.3.7.1. Denmark Computational Biology Market, 2021 - 2033
7.3.7.2. Key Country Dynamics
7.3.7.3. Competitive Scenario
7.3.8. Sweden
7.3.8.1. Sweden Computational Biology Market, 2021 - 2033
7.3.8.2. Key Country Dynamics
7.3.8.3. Competitive Scenario
7.3.9. Norway
7.3.9.1. Norway Computational Biology Market, 2021 - 2033
7.3.9.2. Key Country Dynamics
7.3.9.3. Competitive Scenario
7.4. Asia Pacific
7.4.1. Asia-Pacific Computational Biology Market, 2021 - 2033
7.4.2. Japan
7.4.2.1. Japan Computational Biology Market, 2021 - 2033
7.4.2.2. Key Country Dynamics
7.4.2.3. Competitive Scenario
7.4.3. China
7.4.3.1. China Computational Biology Market, 2021 - 2033
7.4.3.2. Key Country Dynamics
7.4.3.3. Competitive Scenario
7.4.4. India
7.4.4.1. India Computational Biology Market, 2021 - 2033
7.4.4.2. Key Country Dynamics
7.4.4.3. Competitive Scenario
7.4.5. South Korea
7.4.5.1. South Korea Computational Biology Market, 2021 - 2033
7.4.5.2. Key Country Dynamics
7.4.5.3. Competitive Scenario
7.4.6. Thailand
7.4.6.1. Thailand Computational Biology Market, 2021 - 2033
7.4.6.2. Key Country Dynamics
7.4.6.3. Competitive Scenario
7.4.7. Australia
7.4.7.1. Australia Computational Biology Market, 2021 - 2033
7.4.7.2. Key Country Dynamics
7.4.7.3. Competitive Scenario
7.5. Latin America
7.5.1. Latin America Computational Biology Market, 2021 - 2033
7.5.2. Brazil
7.5.2.1. Brazil Computational Biology Market, 2021 - 2033
7.5.2.2. Key Country Dynamics
7.5.2.3. Competitive Scenario
7.5.3. Mexico
7.5.3.1. Mexico Computational Biology Market, 2021 - 2033
7.5.3.2. Key Country Dynamics
7.5.3.3. Competitive Scenario
7.5.4. Argentina
7.5.4.1. Argentina Computational Biology Market, 2021 - 2033
7.5.4.2. Key Country Dynamics
7.5.4.3. Competitive Scenario
7.6. MEA
7.6.1. MEA Computational Biology Market, 2021 - 2033
7.6.2. South Africa
7.6.2.1. South Africa Computational Biology Market, 2021 - 2033
7.6.2.2. Key Country Dynamics
7.6.2.3. Competitive Scenario
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Computational Biology Market, 2021 - 2033
7.6.3.2. Key Country Dynamics
7.6.3.3. Competitive Scenario
7.6.4. UAE
7.6.4.1. UAE Computational Biology Market, 2021 - 2033
7.6.4.2. Key Country Dynamics
7.6.4.3. Competitive Scenario
7.6.5. Kuwait
7.6.5.1. Kuwait Computational Biology Market, 2021 - 2033
7.6.5.2. Key Country Dynamics
7.6.5.3. Competitive Scenario
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share/Position Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. DNAnexus, Inc.
8.4.1.1. Company Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Illumina, Inc.
8.4.2.1. Company Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Thermo Fisher Scientific, Inc.
8.4.3.1. Company Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Schrödinger, Inc.
8.4.4.1. Company Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Compugen
8.4.5.1. Company Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Aganitha AI Inc.
8.4.6.1. Company Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Genedata AG
8.4.7.1. Company Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. QIAGEN
8.4.8.1. Company Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. SIMULATIONS PLUS
8.4.9.1. Company Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Fios Genomics
8.4.10.1. Company Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers